Phase II HCVac study of TG4040 immunotherapeutic in combination with PEGIFNα2a and ribavirin in genotype 1 CHC treatment naïve patients: SVR24 final results

Authors
Category Primary study
JournalJournal of Hepatology
Year 2013
This article has no abstract
Epistemonikos ID: b2687388fd55d7864ac497a6636d8895148de84f
First added on: Feb 05, 2025